Since expression of pluripotent stem cell markers in tumor-derived cancer stem
cells is controversial, we examined the expression of Oct-3/4, Nanog and SOX2 by immunocytochemistry in tumor spheres derived from the breast cancer cell line MCF7.
In a separate experiment, we analyzed the expression of different CD44 variants typically expressed in cancer cells by flow cytometry. While breast cancer stem cells are typically characterized by their CD44+/CD24low expression, little is known about the expression profiles of CD44 variants in those cells.
Download the poster in high resolution pdf format
(presented at the 2009 American Association for Cancer Research)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.